Heptares Therapeutics Limited

Nxera Pharma UK Limited

John Andrew Christopher

Miles Stuart Congreve

Benjamin Gerald Tehan

Sarah Joanne Bucknell

Sarah Joanne Aves

Francesca Deflorian

Jonathan Stephen Mason

Giles Albert Brown

Santosh Shripad Kulkarni

Mark Pickworth

Sukhbinder Singh Klair

Nigel Alan Swain

Mark Mills

Anil Patel

Anne Mary Stephenson

Julie Elaine Cansfield

Andrew David Cansfield

Geraint Jones

Andrew William Phillips

Stephen Paul Watson

Michael Alistair O'brien

Andrea Bortolato

Gregory R Ott

Chris De Graaf

Alicia Perez Higueruelo

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rand n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

The disclosures herein relate to novel compounds of Formula (1); and salts thereof, wherein A, A, Q, X, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

CGRP antagonist compounds

The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Orexin 1 receptor antagonists

The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Oxexin 1 receptor antagonists

The disclosures herein relate to novel compounds of formula

CGRP receptor antagonists

Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

The disclosures herein relate to novel compounds of formula  wherein R, R, Rand Rand n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rare as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rand n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function. 

The disclosures herein relate to novel compounds of formula wherein W, X and Y, Y, Yand Yare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors. 

Orexin receptor antagonists

The disclosures herein relate to novel compounds of formula wherein R, Rand Rare as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

The disclosures herein relate to novel compounds of formula wherein Arand Rare as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Growing community of inventors

Cambridge, United Kingdom

John Andrew Christopher